In the Spotlight
A deadly double standard in AIDS treatment
Philip Stevens, Medical Progress Today, 7-13-07
Among the many unknowns in HIV/AIDS treatment there is one certainty. Once antiretroviral (ARV) treatment begins, drug resistance will inevitably set in amongst a percentage of patients each year, as the virus mutates and adapts - even in the best of medical environments. Those patients that demonstrate resistance to first-line therapies have to switch to second—or even third–line "salvage" therapies, which are considerably more costly to administer and monitor.
Continue reading . . .
· Medical Device Recalls and the FDA Approval Process, Zuckerman, D. M., Brown, P., Nissen, S. E., Archives of Internal Medicine, 6-14-11
· Patent Reform Gets Key Support in House, Julian Pecquet, The Hill, 6-14-11
· $4.3 Billion Pledged at Vaccine Fund-Raiser, Donald G. McNeil Jr., New York Times, 6-13-2011
· Physicians Leaving Practices for health System Employment, Karen Cheung, FierceHealthcare, 6-13-11
More Headlines >>
Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research.
For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at firstname.lastname@example.org, or via telephone at 212.599.7000.
Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at email@example.com, or via telephone at 212.599.7000.
If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line.